Abstract
Background and objectiveThe prognosis of male anal squamous cell carcinoma (MASCC) and female anal squamous cell carcinoma (FASCC) is variable. The influence of tumor subtype on the survival rate and gender is poorly known. Our study is the largest population-based study and aims to outline the difference in survival between MASCC and FASCC patients.MethodsA retrospective population-based study was performed to compare the disease-specific mortalities (DSMs) between genders related to the tumor subtypes. The Surveillance, Epidemiology, and End Results (SEER) program database was employed to obtain the data from January 1988 to December 2014.ResultsA total of 4,516, (3,249 males and 1,267 females), patients with anal squamous cell carcinomas (ASCC) were investigated. The 5-year DSMs were 24.18% and 18.08% for men and women, respectively. The univariate analysis of the male basaloid squamous cell carcinoma (BSCC) and cloacogenic carcinoma (CC) patients demonstrated higher DSMs (P <0.001). Moreover, in the multivariate analysis, BSCC and CC were associated with soaring DSMs in male patients (P < 0.05).ConclusionsIn the cohort of BSCC and CC patients, male patients demonstrated a considerable decrease in survival rate compared to females. A more precise classification of ASCC and individualized management for MASCC are warranted.
Highlights
Anal cancer is a relatively rare neoplasm, accounting for approximately 1% of the gastrointestinal cancers
In the cohort of basaloid squamous cell carcinoma (BSCC) and CC patients, male patients demonstrated a considerable decrease in survival rate compared to females
Over the past few years, studies related to epidemiology and histological features have suggested that male anal squamous cell carcinoma (MASCC) should not be considered as a common disease and called for the need of customized diagnostic and therapeutic strategies
Summary
Anal cancer is a relatively rare neoplasm, accounting for approximately 1% of the gastrointestinal cancers. Anal squamous cell carcinoma (ASCC) is the most common subtype and constitutes 90% of all the anal cancers [4]. Literature reports the significant difference in the prognostic factors, survival outcome, and biological behaviors of www.impactjournals.com/oncotarget tumor in male patients from females [4,5,6]. Soeberg et al [6] report that the women with ASCC have a better prognosis the men. The prognosis of male anal squamous cell carcinoma (MASCC) and female anal squamous cell carcinoma (FASCC) is variable. The influence of tumor subtype on the survival rate and gender is poorly known. Our study is the largest population-based study and aims to outline the difference in survival between MASCC and FASCC patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
